Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis
Open Access
- 27 October 1998
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 95 (22), 13266-13271
- https://doi.org/10.1073/pnas.95.22.13266
Abstract
Amyloid β peptide (Aβ) is thought to play a central role in the pathogenesis of Alzheimer disease (AD). How Aβ induces neurodegeneration in AD is not known. A connection between AD and cholesterol metabolism is suggested by the finding that people with the apolipoprotein E4 allele, a locus coding for a cholesterol-transporting lipoprotein, have a modified risk for both late-onset AD and cardiovascular disease. In the present study we show that both Aβ and submicromolar concentrations of free cholesterol alter the trafficking of a population of intracellular vesicles that are involved in the transport of the reduced form of the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT formazan), the formation of which is a widely used cell viability assay. Treatments that change cellular free cholesterol levels also modulate the trafficking of the MTT formazan-containing vesicles, suggesting that the trafficking of these vesicles may be regulated by free cholesterol under physiological conditions. In addition, Aβ decreases cholesterol esterification and changes the distribution of free cholesterol in neurons. These results suggest that the MTT formazan-transporting vesicles may be involved in cellular cholesterol homeostasis and that the alteration of vesicle transport by Aβ may be relevant to the chronic neurodegeneration observed in AD.Keywords
This publication has 33 references indexed in Scilit:
- Cytotoxic Amyloid Peptides Inhibit Cellular 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐Diphenyltetrazolium Bromide (MTT) Reduction by Enhancing MTT Formazan ExocytosisJournal of Neurochemistry, 1997
- Mechanism of Cellular 3‐(4,5‐Dimethylthiazol‐2‐yl)‐2,5‐Diphenyltetrazolium Bromide (MTT) ReductionJournal of Neurochemistry, 1997
- Amyloid β Toxicity Consists of a Ca2+‐Independent Early Phase and a Ca2+‐Dependent Late PhaseJournal of Neurochemistry, 1996
- Mechanisms of Neuronal Degeneration in Alzheimer's DiseaseNeuron, 1996
- The Niemann-Pick C lesion and its relationship to the intracellular distribution and utilization of LDL cholesterolBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1994
- Regional specificity of membrane instability in Alzheimer's disease brainBrain Research, 1993
- Vitamin E protects nerve cells from amyloid βprotein toxicityBiochemical and Biophysical Research Communications, 1992
- Neurotrophic and Neurotoxic Effects of Amyloid β Protein: Reversal by Tachykinin NeuropeptidesScience, 1990
- A Receptor-Mediated Pathway for Cholesterol HomeostasisScience, 1986
- Amyloid Deposits and AmyloidosisNew England Journal of Medicine, 1980